Back

Eligibility for EMPEROR trials in a real-world heart failure population: data from the Swedish heart failure registry

27 May 2019 (08:36 - 08:42)
Organised by:
Congress Presentation Part of: Rapid Fire 4 - Chronic heart failure - Pharmacology Epidemiology, Prognosis, Outcome HFA Premium Access Heart Failure 2019

About the speaker

Photo
Doctor Tonje Thorvaldsen

Karolinska Institute, Stockholm (Sweden)

14 More presentations in this session

Presentation thumbnail
Heart failure outcomes in patients with diabetes with and without atrial fibrillation - data from the EMPA-REG OUTCOME study
Professor M. Boehm (Homburg, DE)
Abstract Slides Video
Presentation thumbnail
Metformin reduces myocardial oxygen consumption and improves myocardial efficiency in pre-diabetic heart failure patients
Doctor A. Larsen (Herning, DK)
Abstract Slides Video
Presentation thumbnail
Effects of combined uptitration of ACE-inhibitors and beta-blockers in heart failure with reduced ejection fraction
Doctor W. Ouwerkerk (Amsterdam, NL)
Abstract Slides Video
Presentation thumbnail
Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in heart failure patients with mid-range and preserved ejection fraction and clinical outcomes: from the KCHF Registry
Doctor Y. Yoshikawa (Kyoto, JP)
Abstract Slides Video
Presentation thumbnail
The role of candesartan or carvedilol for prevention of anthracycline induced subclinical cardiotoxicity in breast cancer patients.
Doctor M. Lee (La Jolla, US)
Abstract

Access the full session

Session thumbnail
Rapid Fire 4 - Chronic heart failure - Pharmacology

The Event

Event poster

Heart Failure 2019

27 May 2019 08:36 CET
You may be interested in
thumbnail
Congress Presentation
Eligibility for sotagliflozin in a real-world heart failure population based on the SOLOIST-WHF trial enrolment criteria: data from the Swedish Heart Failure Registry
23 May 2022
thumbnail
Webinar
MRAs in heart failure: what's old is new again
10 July 2023
thumbnail
Webinar
Registries to support implementation of care and trial design in heart failure
15 February 2022
thumbnail
Congress Presentation
Factors associated with oral SGLT2 inhibitor use and prognosis in elderly heart failure patients
28 August 2026

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources